Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) is effective in primary humoral immunodeficiency (PI): results from a prospective, open-label, multicenter, phase 3 study

Immune globulin subcutaneous, human – klhw 20% solution (IGSC-C 20%) is a new treatment for patients with PI. The primary objective determined whether the pharmacokinetics (PK) of IGSC-C 20% is noninferior to intravenous (IV) immune globulin injection (human),10% caprylate/chromatography purified (IGIV-C 10%).

Source: Journal of Allergy and Clinical Immunology - January 31, 2020 Category: Allergy & Immunology Authors: John Sleasman, William Lumry, Iftikhar Hussain, H. James Wedner, James Harris, Elsa Mondou, Jiang Lin, Carrie Hames, Montse Querolt, Mark Stein Source Type: research